Drug interactions in critically-ill patients. An important factor in the use of micafungin?;Interacciones farmacológicas en el paciente crítico. ¿un factor relevante para usar micafungina?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue SUPPL. 2, 2011, Pages 33-37

  Garnacho Montero, José ^a   Jiménez Parrilla, Francisco ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Antifungal pharmacokinetics; Drug interactions; Echinocandins; Micafungin

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYTOCHROME P450; CYTOCHROME P450 3A4; ECHINOCANDIN; FLUCONAZOLE; GLYCOPROTEIN P; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE;

ARTICLE; CRITICALLY ILL PATIENT; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; KIDNEY FAILURE; MYCOSIS; NEPHROTOXICITY;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CRITICAL ILLNESS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; INFANT, NEWBORN; LIPOPEPTIDES; MICROSOMES, LIVER; MYCOSES; P-GLYCOPROTEIN; TRIAZOLES;

EID: 79953224087     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(11)70007-6     Document Type: Article

References (42)

1. C. Lumbreras, M. Lizasoain, and J.M. Aguado Antifúngicos de uso sistémico Enferm Infecc Microbiol Clin 21 2003 366 380
2. D.W. Bates, L. Su, D.T. Yu, G.M. Chertow, D.L. Seger, and D.R.J. Gomes Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693 (Pubitemid 32221925)
3. J.R. Wingard, P. Kubilis, L. Lee, G. Yee, M. White, and L. Walshe Clinical significacne of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis Clin Infect Dis 29 1999 1402 1407 (Pubitemid 30022731)
4. B. Dupont Overview of the lipid formulations of amphotericin B J Antimicrob Chemother 49 Suppl 1 2002 31 36 (Pubitemid 34162654)
5. P.O. Gubbins, and S. Heldenbrand Clinically relevant drug interactions of current antifungal agents Mycoses 53 2009 95 113
6. P.O. Gubbins, and J.R. Amsden Drug-drug interactions of antifungal agents and implications for patient care Expert Opin Pharmacother 6 2005 2231 2243 (Pubitemid 41582210)
7. K. Venkatakrishnan, L.L. Von Moltke, and D.J. Greenblatt Effects of the antifungal agents on oxidative drug metabolism: clinical relevance Clin Pharmacokinet 38 2000 111 180 (Pubitemid 30122116)
8. R.M. Cadle, G.J. Zenon 3rd, M.C. Rodríguez-Barradas, and R.J. Hamill Fluconazole-induced symptomatic phenytoin toxicity Ann Pharmacother 28 1994 191 195 (Pubitemid 24073455)
9. J. Papadopoulos, and P.L. Smithburger Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations Crit Care Med 38 2010 S126 S135
10. D. Panomvana Na Ayudhya, N. Thanompuangseree, and S. Tansuphaswadikul Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS Clin Pharmacokinet 43 2004 725 732 (Pubitemid 39159002)
11. J. Fernández Águila, O. Crombert Ramos, I. Billares Álvarez, and R. Pons Vázquez Resistencia a drogas mediadas por la glicoproteína-P Rev Cubana Oncol 14 1998 111 120
12. K. Yasuda, L.B. Lan, D. Sanglard, K. Furuya, J.D. Schuetz, and E.G. Schuetz Interaction of cytochrome P450 3A inhibitors with P-glycoprotein J Pharmacol Exp Ther 303 2002 323 332
13. A.H. Saad, D. DePestel, and P. Carver Factors influencing the magnitude and clinical significance of drug interactions between azole fungals and select immunosuppressants Pharmacotherapy 26 2006 1730 1744 (Pubitemid 44885328)
14. L.B. Johnson, and C.A. Kauffman Voriconazole: a new triazole antifungal agent Clin Infect Dis 36 2003 630 637 (Pubitemid 36259570)
15. A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 2008 201 211 (Pubitemid 351269158)
16. S. Jeong, P.D. Nguyen, and Z. Desta Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A Antimicrob Agents Chemother 53 2009 541 551
17. A.J. Romero, P. Le Pogamp, L.G. Nilsson, and N. Wood Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients Clin Pharmacol Ther 71 2002 226 234 (Pubitemid 34311451)
18. P. Krieter, B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney Disposition of posaconazole following single-dose oral administration in healthy subjects Antimicrob Agents Chemother 48 2004 3543 3553
19. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr, T.F. Calandra, and J.E. Edwards Jr Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
20. J.E. Bennet Echinocandins for candidemia in adults without neutropenia N Engl J Med 355 2006 1154 1159
21. A.J. Sucher, E.B. Chahine, and H.E. Balcer Echinocandins: the newest class of antifungals Ann Pharmacother 43 2009 1647 1657
22. J.A. Stone, E.M. Migoya, L. Hickey, G.A. Winchell, P.J. Deutsch, and K. Ghosh Potential for interactions between caspofungin and nelfinavir or rifampin Antimicrob Agents Chemother 48 2004 4306 4314 (Pubitemid 39434891)
23. J.A. Stone, X. Xu, G.A. Winchell, P.J. Deutsch, P.G. Pearson, and E.M. Migoya Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma Antimicrob Agents Chemother 48 2004 815 823 (Pubitemid 38280330)
24. P. Sandhu, W. Lee, X. Xu, B.F. Leake, M. Yamakazi, and J.A. Stone Hepatic uptake of the novel antifungal agent caspofungin Drug Metab Dispos 33 2005 676 682 (Pubitemid 40593883)
25. K.A. Marr, R. Hachem, G. Papanicolaou, J. Somani, J.M. Arduino, and C.J. Lipka Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A Transpl Infect Dis 6 2004 110 116 (Pubitemid 40013050)
26. C. Sanz-Rodríguez, R. Arranz, J.M. Cisneros, P.J. García-Sánchez, M. Jurado, and J. López Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics Swiss Med Wkly 135 2005 658 659 (Pubitemid 41811598)
27. S. Holland, J. Stone, P. Wickersham, P. Deutsch, G. Winchell, and M. Herney Drug interactions between caspofungin and tacrolimus Program and Abstracts of the 41th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, American Society of Microbiology December 16-19, Abstract A-13 2001
28. D.W. Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151 (Pubitemid 37222342)
29. J.A. Dowell, M. Stogniew, D. Krause, T. Henkel, and I.E. Weston Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine J Clin Pharmacol 45 2005 227 233 (Pubitemid 40490447)
30. B.D. Brielmaier, E. Casabar, C.M. Kutzeborn, P.S. Mckinnon, and D.J. Ritchie Early clinical esperience with anidulafungin at a large tertiary care medical center Pharmacotherapy 28 2008 64 73
31. J.R. Hurren, S.L. Davis, and JA. Vázquez What is the risk of disulfiram-like reaction with anidulafungin and metronidazole administration? 47th Interscience Conference on Antimicrobial Agents and Chemotheraphy Annual Meeting Chicago, IL 2007
32. M.F. Hebert, D.K. Blough, R.W. Townsend, M. Allison, D. Buell, and J. Keirns Concomitant tacrolimus and mica-fungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 2005 1018 1024 (Pubitemid 41192360)
33. M.F. Hebert, R.W. Townsend, S. Austin, G. Balan, D.K. Blough, and D. Buell Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers J Clin Pharmacol 45 2005 954 960 (Pubitemid 41060236)
34. G. Krishna, D. Vickery, and L. Ma Effect of posaconazole on pharmacokinetics (PK) of caspofungin and micafungin [abstract no. A-015] 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and. 46th Annual Meeting of the Infectious Diseases Society of America Washington DC, Oct25-28 2008
35. Y. Muraki, T. Iwamoto, Y. Kagawa, H. Sakurai, M. Usui, and S. Isaji The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction Biol Pharm Bull 32 2009 750 754
36. S. Shimoeda, S. Ohta, H. Kobayashi, H. Saitou, A. Kubota, and S. Yamato Analysis of the blood level of micafungin involving patients with haematological diseases: new findings regarding combination therapy witht acrolimus Biol Pharm Bull 28 2005 477 480 (Pubitemid 40879971)
37. T. Sakaeda, K. Iwaki, M. Kakumoto, M. Nishikawa, T. Niwa, and J.S. Jin Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs J Pharm Pharmacol 57 2005 759 764 (Pubitemid 40694884)
38. G. Krishna, D. Vickery, L. Ma, X. Yu, C. Noren, and E. Power Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin J Clin Pharmacol 2010 May 20 [Epub ahead of print]
39. M. Kawada, N. Fukuoka, M. Kondo, K. Okazaki, T. Kusaka, and K. Kawada Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants Pediatr Infect Dis J 28 2009 840 842
40. D.K. Benjamin Jr, P.B. Smith, A. Arrieta, L. Castro, P.J. Sánchez, and D. Kaufman Safety and pharmacokinetics of repeat-dose micafungin in young infants Clin Pharmacol Ther 87 2010 93 99
41. P.B. Smith, T.J. Walsh, W. Hope, A. Arrieta, A. Takada, and L.L. Kovanda Pharmacokinetics of an elevated dosage of micafungin in premature neonates Pediatr Infect Dis J 28 2009 412 415
42. F. Queiroz-Telles, E. Berezin, G. Leverger, A. Freire, A. Van der Vyver, T. Chotpitayasunondh Micafungin Invasive Candidiasis Study Group Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial Pediatr Infect Dis J 27 2008 820 826